#1 dispensed basal insulin as prescribed by Endocrinologists*
Find out if Tresiba® is covered in your province!
Covered by most provincial formularies across Canada†
Ask your healthcare team today if Tresiba® is right for you!
Simplified Chinese (CN)
Traditional Chinese (HK)
Tresiba® is indicated for once-daily treatment of adults with diabetes mellitus to improve glycemic control. Tresiba® is also indicated for the treatment of pediatric patients (>2 years old) with type 1 diabetes mellitus.
Not recommended for treatment of diabetic ketoacidosis.
During episodes of hypoglycemia
Most serious warnings and precautions:
Hypoglycemia is the most common adverse effect of insulin
Glucose monitoring is required
Uncorrected hypo- or hyperglycemic reactions can cause loss of consciousness, coma and even death
Use caution and medical supervision when converting insulin products
Inspect visually prior to administration and only use if solution appears clear and colourless
Do not mix with any other insulin, administer intravenously or use in insulin infusion pumps
Other relevant warnings and precautions:
Refer to respective product monographs for concomitant oral antidiabetic agents for their warnings and precautions
Stress or concomitant illness, especially infections and febrile conditions, may change insulin requirements
Tresiba® should not be diluted
Combination with thiazolidinediones (TZD) not indicated in type 2 diabetes; can cause heart failure and edema
Risks associated with sharing insulin delivery devices
Risk of hypokalemia
Dosing may need to be adjusted in patients with renal and/or hepatic impairment
Risk of immune responses (e.g., systemic allergic reactions or antibody production)
Pregnant and nursing women
For more information:
Please consult the Product Monograph at www.Tresibapm-e.ca for more information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.
The Product Monograph is also available by calling us at 1-800-465-4334.